#United States #Dallas #BRC Therapeutics #George Hodgin #Nucleate Summit

BRC Therapeutics CEO George Hodgin to Speak at Nucleate Global Summit 2026

BRC Therapeutics, a forward-looking pharmaceutical company dedicated to advancing therapies for neurological and inflammatory diseases, has made an exciting announcement. Founder and CEO, George Hodgin, is set to participate in a fireside chat at the prestigious Nucleate Global Summit 2026. This annual summit, a gathering point for innovators in biotechnology, will be hosted from August 16 to 18 at the iconic Southfork Ranch in Dallas, Texas.

The session will be titled "Leading Under Pressure: From Navy SEAL to Biotech CEO." Hodgin will share his unique experiences as a former U.S. Navy SEAL officer, discussing how the leadership skills honed in the high-stakes environments of counter-terrorism operations influence his approach to leading a clinical-stage pharmaceutical company.

The Journey from Military to Medicine

Hodgin’s path to establishing BRC Therapeutics is both remarkable and inspiring. Following his military career, he recognized a significant gap in the availability of FDA-approved cannabinoid therapeutics while assisting a fellow veteran with medical appointments. This revelation was pivotal, leading him to found BRC Therapeutics with an aim to develop therapies that leverage cannabis-based treatments free from the unpredictability associated with recreational use.

At BRC, the focus is on a pipeline of investigational cannabinoid medications designed to offer effective solutions for chronic pain and neurological disorders. The company is advancing these products through stringent FDA approval processes, promising to provide targeted relief for conditions such as:

• - Complex Regional Pain Syndrome (CRPS)
• - Aromatase Inhibitor-Induced Arthralgia (AIIA)
• - Restless Legs Syndrome (RLS)
• - An undisclosed neurological condition

A Unique Approach to Drug Development

The innovative medicines developed by BRC Therapeutics employ a multimodal approach, combining cannabinoids at specific ratios to ensure efficacy and reliability. Unlike recreational cannabis, the therapeutics are engineered for predictable effects, thus providing a safer option for those in need of relief from chronic ailments. The company boasts a robust patent portfolio and operates under a DEA Schedule I Bulk Manufacturing Registration, emphasizing its commitment to compliance and quality.

Leadership Lessons from the Battlefield

Reflecting on his unique background, Hodgin states, "My time in special operations taught me that clarity, trust, and calm under pressure are what separate successful teams from those that falter. Building a biotech company through clinical development is akin to navigating through a high-stakes mission, it comes with its own set of regulatory, technical, and economic challenges aimed at ultimately serving patients in need."

This ethos not only informs his leadership style but also embodies the spirit of resilience and commitment that is crucial in the biotech field. At the Nucleate Global Summit, Hodgin aims to share these insights, connecting with fellow founders, scientists, industry representatives, and investors who are shaping the future of healthcare through innovative solutions.

Looking Ahead

As BRC Therapeutics continues to forge ahead, Hodgin's insights gained from military experience will undoubtedly serve as a beacon for fellow innovators striving to make a personal impact in the realm of health and wellness. This blend of disciplines - from battlefield to lab - presents a unique narrative that speaks to the heart of entrepreneurship, underscoring the importance of leadership in both high-pressure environments and pioneering therapeutic development.

In conclusion, George Hodgin’s participation in the Nucleate Global Summit 2026 promises not just to inspire, but also to foster a meaningful dialogue about the future of biotechnology and the potential it holds for improving patient outcomes. For more information about BRC Therapeutics and its innovative mission, visit brctherapeutics.com.